Additional file 2 of Repurposing beta-3 adrenergic receptor agonists for Alzheimer’s disease: beneficial effects in a mouse model

Additional file 2. Other AD markers not affected by CL-316,243 treatment. Relative optical density of proteins normalized on actin measured in detergent-soluble fraction of hippocampus homogenates by Western Blot. Data are represented as mean ± SD, n = 9-12 per group. Abbreviations: AKT: protein kinase B; APP: amyloid precursor protein; BACE-1: beta-secretase 1; GFAP: glial fibrillary acidic protein; GLUT1: glucose transporter 1; GSK3β, glycogen synthase kinase 3β; IDE: insulin degrading enzyme; LRP1: low density lipoprotein receptor related protein 1; PSD95: post-synaptic density 95; RAGE: receptor of advanced glycation end products; sAPPα: soluble α-APP

附加文件2：不受CL-316,243处理影响的其他阿尔茨海默病（Alzheimer's Disease，AD）标志物。采用蛋白质印迹（Western Blot）技术，检测海马匀浆去垢剂可溶性组分中以肌动蛋白（actin）为内参归一化的蛋白质相对光密度。数据以平均值±标准差（SD）表示，每组n=9~12。缩写说明：AKT：蛋白激酶B（protein kinase B）；APP：淀粉样前体蛋白（amyloid precursor protein）；BACE-1：β-分泌酶1（beta-secretase 1）；GFAP：胶质纤维酸性蛋白（glial fibrillary acidic protein）；GLUT1：葡萄糖转运蛋白1（glucose transporter 1）；GSK3β：糖原合成激酶3β（glycogen synthase kinase 3β）；IDE：胰岛素降解酶（insulin degrading enzyme）；LRP1：低密度脂蛋白受体相关蛋白1（low density lipoprotein receptor related protein 1）；PSD95：突触后致密蛋白95（post-synaptic density 95）；RAGE：晚期糖基化终产物受体（receptor of advanced glycation end products）；sAPPα：可溶性α-APP（soluble α-APP）